Compass Therapeutics, Inc. $CMPX Holdings Cut by Monashee Investment Management LLC

Monashee Investment Management LLC lowered its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 20.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,000,000 shares of the company’s stock after selling 250,000 shares during the period. Compass Therapeutics comprises about 3.0% of Monashee Investment Management LLC’s investment portfolio, making the stock its 14th biggest holding. Monashee Investment Management LLC owned about 0.56% of Compass Therapeutics worth $5,370,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of CMPX. Russell Investments Group Ltd. lifted its holdings in Compass Therapeutics by 3,933.7% in the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after acquiring an additional 7,592 shares during the last quarter. Creative Planning bought a new stake in shares of Compass Therapeutics during the second quarter valued at approximately $30,000. Flagship Harbor Advisors LLC bought a new stake in shares of Compass Therapeutics during the fourth quarter valued at approximately $32,000. Strs Ohio bought a new stake in shares of Compass Therapeutics during the first quarter valued at approximately $34,000. Finally, CIBC Bancorp USA Inc. bought a new stake in shares of Compass Therapeutics during the third quarter valued at approximately $37,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Price Performance

NASDAQ CMPX opened at $2.01 on Friday. Compass Therapeutics, Inc. has a 12 month low of $1.61 and a 12 month high of $6.88. The firm has a market capitalization of $361.98 million, a PE ratio of -4.90 and a beta of 0.89. The company’s 50 day simple moving average is $3.24 and its 200 day simple moving average is $4.78.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). Sell-side analysts anticipate that Compass Therapeutics, Inc. will post -0.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on CMPX shares. William Blair reaffirmed an “outperform” rating on shares of Compass Therapeutics in a report on Thursday, March 5th. Raymond James Financial cut Compass Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 28th. Canaccord Genuity Group cut their price target on Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, April 28th. Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a report on Thursday, June 4th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $30.00 price target on shares of Compass Therapeutics in a report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.91.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical?stage biotechnology company dedicated to the discovery and development of novel immuno?oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti?tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47?SIRP? pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.